跳至主要内容
临床试验/NCT07400458
NCT07400458招募中不适用

Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration to Evaluate Its Safety in Patients With Acute Myocardial Infarction

Pharmicell Co., Ltd.1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2022年3月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
Rate of AESI

研究概览

简要总结

This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

详细描述

To evaluate the safety for 60 months after a single dose of Hearticellgram-AMI in patients with Acute Myocardial Infarction.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Those who had administered Hearticellgram-AMI
  • Those who voluntarily agreed in writing to participate in this investigation

排除标准

  • 未提供

研究组 & 干预措施

Hearticellgram-AMI

Experimental

Patients with Acute Myocardial Infarction who had administered Hearticellgram-AMI.

干预措施: Hearticellgram-AMI (Biological)

结局指标

主要结局

Rate of AESI

时间窗: For 5 years

death, neoplasms or malignancies in tissues or organs, Immune response

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验